Validation study targets sub-3-minute results to capture global roadside testing market and significantly reduce analysis time from 10 minutes U.S. Roadside drug testing market projected to reach...
NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing...
Study results finalized on schedule support FDA clearance and planned U.S. commercial launch Company advances second phase of clinical program for 510(k) submission with method comparison, usability,...
NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing...
Successful delivery in partnership with Syrma Johari validates manufacturing scale, strengthens commercial readiness, and supports planned U.S. market entry in 2026 Partnership on track to deliver...
NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing...
First half fiscal 2026 revenue surpasses $2 million, up 36% year-over-year Reader sales more than double to 104% year-over-year for the second quarter, demonstrating razor-razorblade model momentum...
Expected record fiscal second quarter revenue increase driven by expanding customer base and strong growth across all product categories Reader sales expected to post year-over-year growth of more...
Clinical studies designed to support FDA clearance and planned commercial launch into the world’s largest drug screening market Company anticipates full data analysis by the end of March 2026;...
NEW YORK, Jan. 02, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive...